Prazinezumab reduces motor progression - Cure Parkinson's
Prazinezumab reduces motor progression
alzforum.org/therapeutics/p...
"Background
Prasinezumab is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Genetic and pathological evidence suggest that this protein plays a central role in the pathogenesis of Parkinson's disease (PD) and other α-synucleinopathies, such as dementia with Lewy bodies (DLB). In mouse models of PD and DLB, the mouse version of PRX002, 9E4, has been reported to reduce a C-terminally truncated form of α-synuclein that is considered neurotoxic, as well as α-synuclein propagation from cell to cell, neuropathology, and behavioral endpoints (e.g., Games et al., 2013; Games et al., 2014; Masliah et al., 2011)."
This trial result is a fail. The sum of UPDRS parts 1 2 and 3 was as close to identical as could be between the test arms and the placebo arm. The progression as measured by part 3 diverged by a single point over the course of a year, with the test arms being one point less progression. The chart they do not show you is the parts one and two test arms progressing by one point more than placebo. A single UPDRS point is insignificant. This treatment had no effect.
Image credit: www[.]youtube.com/watch?v=sPh1KG9J4S0&t=27s
Looks very promising...
Listening to this back, they report the first study as a fail I.e. the PASADENA study, which they describe as not meeting its target end points over its one year duration They do make a note as to the combined scale's lack of sensitivity for a study so (relatively) short.
The exciting part for me is the interim data they report towards the end re. the Open Label Extension. This study runs for 48 months i. e. nearly 4 years.
The data on the screenshot is a cut of interim data taken at the 42 month period, which shows major differences between the two groups on the treatment over this longer duration compared to the gray line I.e. a control group not on the treatment.
The red lines are my markups but indicate that, at the 42 month point, the two groups on the drug had progressed about half as much non the UPDRS (approx. 4 rather than 8 points of progression).
Fecal Transplants Relieve Constipation and Motor, Non-Motor Symptoms
Non-motor symptom medication
Progression of PD.
Progression of PD
Rate of Progression.
